Cannabis Stock News: Aphria Inc. (TSX: $APHA.TO) (Nasdaq: $APHA) Announces Record Second Quarter Fiscal Year 2021 Results

LEAMINGTON, ON - January 14, 2021 (Investorideas.com Newswire) Aphria Inc. ("Aphria," "we," or the "Company") (TSX: APHA) (Nasdaq: APHA), a leading global cannabis-lifestyle consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported its financial results for the second quarter and six months ended November 30, 2020. All amounts are expressed in Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.

Dr. Birmingham is an expert in the treatment and study of eating and weight disorders. He has pioneered several new internationally recognized treatments. He has more than 30 years of experience in eating disorder and obesity research and treatment and has 280 publications including 131 referenced articles, 23 invited chapters, and 9 books. He was Head of General Internal Medicine at St. Paul's Hospital and UBC, Head of the Obesity Clinic at St. Paul's Hospital, Leader of the BC Eating Disorders Epidemiology Project in the Centre for Health Evaluation and Outcome Sciences, BC Provincial Director of Eating Disorders, and Medical Director of the Woodstone Residential Treatment Centre for Eating Disorders. He is a Member of the Brain Research Centre at UBC.

His expertise includes eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorder, avoidant/restrictive food intake disorder (ARFID), phobia, emetophobia, obesity, imaging of the brain using LORETA 3D electrical brain scans, and treatment using LORETA neurofeedback, vagus nerve stimulation and transcranial electrical stimulation.

Dr. Birmingham's research at UBC includes: nutrition and its relation to brain function, ambient temperature and its effect on activity and brain function, malnutrition and micronutrients, and the epidemiology, complications, and treatment of eating disorders and obesity.

Dr Birmingham says, "The problem with the treatment of obesity is primarily that of weight maintenance. Most people lose weight, but they rarely maintain. Psilocybin has the potential to serve as a new and different tool to help people lose weight and maintain their weight loss by changing neural pathways. Changed habits and cognitions can increase caloric expenditure related to non-exercise and exercise energy expenditure and reset the behaviours and cognitions that link life stress and trauma to eating behaviour."

NeonMind is currently conducting a preclinical trial at the University of British Columbia researching the administration of psilocybin as a treatment to aid in weight loss and it is now engaging its full team to develop its Phase 2 Human Clinical Trial as the next step in its drug development.

Obesity is the cause behind many diseases and other health problems and has been formally recognized by the World Health Organization ("WHO") as a global epidemic. According to WHO:

• 2.8 million people die each year as a result of being overweight or obese; and
• In 2016, more than 1.9 billion adults, 18 years and older, were overweight.

About NeonMind Biosciences Inc.

NeonMind is developing and commercializing products that contain legal medicinal mushrooms and products that may contain psychedelic compounds. Its first proposed drug candidate involves the administration of psilocybin (a complex organic compound found in psychedelic mushrooms) as a treatment for obesity and related illnesses for which NeonMind has started a preclinical trial at the University of British Columbia. NeonMind has filed five U.S. provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogues or by administering psilocybin or its analogue in conjunction with therapy or other treatments. NeonMind is also pursuing commercialization of its catalogue of proprietary medicinal mushroom product formulas. It recently launched a collection of four mushroom-infused coffees containing medicinal mushrooms Lion's Mane, Turkey Tail, Reishi and Cordyceps. The NeonMind eCommerce platform launched in November 2020 at www.neonmind.com for direct to consumer sales.

For more information on NeonMind, go to www.NeonMindbiosciences.com or buy NeonMind mushroom infused coffee at www.NeonMind.com.

Penny White, President & CEO

Brittany Whitmore
Professional Noisemaker
CEO and Principal Publicist
Exvera Communications Inc.
Phone: +1.778.238.6096
Email: Brittany@Exvera.com

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Buy a cannabis guest post on Investorideas.com